Abstract A014: Inhibition of KrasG12D with a novel small molecule inhibitor alters the pancreatic cancer microenvironment
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-a014
Abstract: Approximately 90% of pancreatic ductal adenocarcinoma (PDAC) patients harbor an oncogenic KRAS mutation, with Gly-to-Asp mutations (KrasG12D) being most common. PDAC is characterized by a robust, immunosuppressive tumor microenvironment that is rich in myeloid-derived suppressor… read more here.
Keywords: small molecule; mrtx1133; microenvironment; inhibition krasg12d ... See more keywords
Abstract B032: KRAS copy number variation and mutant allele fractions predict in vitro response of PDX-derived human pancreatic cancer cell lines to KRASG12D inhibitor MRTX1133
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Cancer Research"
DOI: 10.1158/1557-3125.ras23-b032
Abstract: Introduction: KRASG12D is the most common KRAS mutation in pancreatic ductal adenocarcinoma (PDAC). It is well known that activating point mutations in one allele are sufficient for tumor growth in patients harboring KRASG12D mutations and… read more here.
Keywords: cell lines; mrtx1133; copy number; pdx derived ... See more keywords